Novalpina dispute: A masterclass in misalignment
The mid-market firm's troubles highlight the rare risk of members of a GP not seeing eye-to-eye on what's best for their LPs.
29 July 2021•3 mins read
The mid-market firm's troubles highlight the rare risk of members of a GP not seeing eye-to-eye on what's best for their LPs.
Is an elevated hurdle rate a good idea?
15 October 2026 · 3 mins read
Private equity’s growing complexity calls for inclusive expertise
8 October 2026 · 2 mins read
Flipping the OP script
1 October 2026 · 2 mins read
The thorny issue of LP incentivisation
24 September 2026 · 2 mins read
Pie or good government? Pay-to-play's unintended consequences
17 September 2026 · 4 mins read
The ‘open survival ending’ is where most zombie funds are likely headed
10 September 2026 · 3 mins read
PE must be a good sport when it comes to sports investing
3 September 2026 · 2 mins read
